Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.68 |
| ▸ | TNF | P01375 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515814 | 0.95 | MEN1 (0.66) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL5512040 | 0.91 | MEN1 (0.61) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL4441275 | 0.90 | KMT2A (0.73) | MEN1KMT2ATP53MAPTRAB9A | |
| SCHEMBL4889555 | 0.89 | MEN1 (0.60) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL825515 | 0.87 | MEN1 (0.71) | MEN1KMT2ATP53MAPTPOLB | |
| SCHEMBL476983 | 0.87 | PDE4A (0.69) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL717039 | 0.87 | PDE4A (0.69) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL29840774 | 0.87 | PDE4A (0.69) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL5941456 | 0.87 | PDE4A (0.69) | MEN1KMT2ATP53TNFMAPT | |
| SCHEMBL23706241 | 0.86 | MEN1 (0.82) | MEN1KMT2ATP53MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | claimed |
| CN-105873611-A | Compositions and methods for the treatment of viral diseases with PDE4 modulators | 细胞基因公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20090010886-A1 | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione | CELGENE CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010886-A1 | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione | IL2, MCL1, IL1A | MEN1 389/4885KMT2A 1703/4885TP53 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.